AbbVie (ABBV) Tops Q2 EPS by 1c; raises guidance

AbbVie (NYSE: ABBV) reported Q2 EPS of $2.97, $0.01 better than the analyst estimate of $2.96. Revenue for the quarter came in at $15.42 billion versus the consensus estimate of $14.99 billion.

GUIDANCE:

AbbVie sees FY2025 EPS of $11.88-$12.08, versus the consensus of $11.98.

For earnings history and earnings-related data on AbbVie (ABBV) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Stripe, Advent In Talks To Buy Paypal - WSJ
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15